Unilateral Prostate Cancer Cannot be Accurately Predicted in Low-Risk Patients

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 3, 2010, Pages 784-787

  Isbarn, Hendrik ^a,b   Karakiewicz, Pierre I ^b   Vogel, Susanne ^a   Jeldres, Claudio ^b   Lughezzani, Giovanni ^b,c   Briganti, Alberto ^c   Montorsi, Francesco ^c   Perrotte, Paul ^d   Ahyai, Sascha A ^a   Budäus, Lars ^a   Eichelberg, Christian ^a   Heuer, Roman ^a   Köllermann, Jens ^a   Sauter, Guido ^a   Schlomm, Thorsten ^a   Steuber, Thomas ^a   Haese, Alexander ^a   Zacharias, Mario ^a   Fisch, Margit ^a   Heinzer, Hans ^a   Huland, Hartwig ^a   Chun, Felix K H ^a   Graefen, Markus ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Hemiablative therapy; Prostate biopsy; Prostate cancer; Radical prostatectomy; Unilateral

Indexed keywords

CONCENTRATION OF; CONFIDENCE INTERVAL; GOLD STANDARDS; LOGISTIC REGRESSION MODELS; MULTI VARIABLES; MULTIVARIABLE ANALYSIS; PROSTATE BIOPSY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADICAL PROSTATECTOMY; THERAPEUTIC MODALITY;

COMPRESSED AIR MOTORS; DISEASES; REGRESSION ANALYSIS; UROLOGY;

BIOPSY;

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR ABLATION;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 77952563885     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.068     Document Type: Article

References (21)

1. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146-8151
2. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., Tomaszewski J.E., Renshaw A.A., Kaplan I., Beard C.J., and Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
3. Polascik T.J., Mayes J.M., Sun L., Madden J.F., Moul J.W., and Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: Implications for unilateral ablative therapy. Prostate 68 (2008) 1380-1386
4. Mouraviev V., Mayes J.M., Sun L., Madden J.F., Moul J.W., and Polascik T.J. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110 (2007) 906-910
5. Bahn D.K., Silverman P., Lee Sr. F., Badalament R., Bahn E.D., and Rewcastle J.C. Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol 20 (2006) 688-692
6. Ritch C.R., and Katz A.E. Update on cryotherapy for localized prostate cancer. Curr Urol Rep 10 (2009) 206-211
7. Lambert E.H., Bolte K., Masson P., and Katz A.E. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69 (2007) 1117-1120
8. Onik G., Vaughan D., Lotenfoe R., Dineen M., and Brady J. "Male lumpectomy": Focal therapy for prostate cancer using cryoablation. Urology 70 (2007) 16-21
9. Ellis D.S., Manny Jr. T.B., and Rewcastle J.C. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 70 (2007) 9-15
10. Scales Jr. C.D., Presti Jr. J.C., Kane C.J., Terris M.K., Aronson W.J., Amling C.L., and Freedland S.J. Predicting unilateral prostate cancer based on biopsy features: Implications for focal ablative therapy--Results from the SEARCH database. J Urol 178 (2007) 1249-1252
11. Tareen B., Godoy G., Sankin A., Temkin S., Lepor H., and Taneja S.S. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?. BJU Int 104 (2009) 195-199
12. Yoon G.S., Wang W., Osunkoya A.O., Lane Z., Partin A.W., and Epstein J.I. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol 179 (2008) 2203-2206
13. Greene F.L. The American Joint Committee on Cancer: Updating the strategies in cancer staging. Bull Am Coll Surg 87 (2002) 13-15
14. McNeal J.E., Redwine E.A., Freiha F.S., and Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 (1988) 897-906
15. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
16. Arora R., Koch M.O., Eble J.N., Ulbright T.M., Li L., and Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100 (2004) 2362-2366
17. Byar D.P., and Mostofi F.K. Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer 30 (1972) 5-13
18. Schroder F.H., and Roobol M.J. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol 19 (2009) 227-231
19. Chun F.K., Briganti A., Graefen M., Montorsi F., Porter C., Scattoni V., Gallina A., Walz J., Haese A., Steuber T., Erbersdobler A., Schlomm T., Ahyai S.A., Currlin E., Valiquette L., Heinzer H., Rigatti P., Huland H., and Karakiewicz P.I. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol 52 (2007) 436-444
20. Chun F.K., Briganti A., Graefen M., Porter C., Montorsi F., Haese A., Scattoni V., Borden L., Steuber T., Salonia A., Schlomm T., Latchemsetty K., Walz J., Kim J., Eichelberg C., Currlin E., Ahyai S.A., Erbersdobler A., Valiquette L., Heinzer H., Rigatti P., Huland H., and Karakiewicz P.I. Development and external validation of an extended repeat biopsy nomogram. J Urol 177 (2007) 510-515
21. Singh H., Canto E.I., Shariat S.F., Kadmon D., Miles B.J., Wheeler T.M., and Slawin K.M. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 171 (2004) 1089-1092